Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.
Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke DT, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel HD, Sebastian M, Gattenlöhner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Büttner R, Wolf J, Hoffmann W. Kästner A, et al. Among authors: sebastian m. Lancet Reg Health Eur. 2023 Nov 22;36:100788. doi: 10.1016/j.lanepe.2023.100788. eCollection 2024 Jan. Lancet Reg Health Eur. 2023. PMID: 38034041 Free PMC article.
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J. Sebastian M, et al. J Thorac Oncol. 2010 Jul;5(7):1060-7. doi: 10.1097/JTO.0b013e3181d95dd4. J Thorac Oncol. 2010. PMID: 20526206 Free article. Clinical Trial.
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC). Hoffknecht P, et al. J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380. J Thorac Oncol. 2015. PMID: 25247337 Free PMC article.
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. Scheffler M, et al. Among authors: sebastian m. Oncotarget. 2015 Apr 30;6(12):10577-85. doi: 10.18632/oncotarget.3387. Oncotarget. 2015. PMID: 25868855 Free PMC article.
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Heigener DF, et al. Among authors: sebastian m. Oncologist. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9. Oncologist. 2015. PMID: 26354527 Free PMC article.
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J. Kron A, et al. Among authors: sebastian m. Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333. Ann Oncol. 2018. PMID: 30165392 Free PMC article.
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Michels S, et al. Among authors: sebastian m. J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. J Thorac Oncol. 2019. PMID: 30978502 Free article. Clinical Trial.
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, Griesinger F, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, Gautschi O, Geissinger E, Haneder S, Ihle MA, Kopp HG, de Langen AJ, Martinez-Marti A, Nogova L, Persigehl T, Plenker D, Puesken M, Rodermann E, Rosenwald A, Scheel AH, Scheffler M, Spengler W, Seggewiss-Bernhardt R, Brägelmann J, Sebastian M, Vrugt B, Hellmich M, Sos ML, Heukamp LC, Felip E, Merkelbach-Bruse S, Smit EF, Büttner R, Wolf J. Michels S, et al. Among authors: sebastian m. JCO Precis Oncol. 2019 Mar 27;3:PO.18.00210. doi: 10.1200/PO.18.00210. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914023 Free PMC article.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M; CRISP Registry Group. Griesinger F, et al. Among authors: sebastian m. Lung Cancer. 2021 Feb;152:174-184. doi: 10.1016/j.lungcan.2020.10.012. Epub 2020 Nov 2. Lung Cancer. 2021. PMID: 33358484 Free article.
644 results